<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35711381</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2297-055X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in cardiovascular medicine</Title><ISOAbbreviation>Front Cardiovasc Med</ISOAbbreviation></Journal><ArticleTitle>Brief Research Report: Quantitative Analysis of Potential Coronary Microvascular Disease in Suspected Long-COVID Syndrome.</ArticleTitle><Pagination><StartPage>877416</StartPage><MedlinePgn>877416</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">877416</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcvm.2022.877416</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Case series have reported persistent cardiopulmonary symptoms, often termed long-COVID or post-COVID syndrome, in more than half of patients recovering from Coronavirus Disease 19 (COVID-19). Recently, alterations in microvascular perfusion have been proposed as a possible pathomechanism in long-COVID syndrome. We examined whether microvascular perfusion, measured by quantitative stress perfusion cardiac magnetic resonance (CMR), is impaired in patients with persistent cardiac symptoms post-COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Our population consisted of 33 patients post-COVID-19 examined in Berlin and London, 11 (33%) of which complained of persistent chest pain and 13 (39%) of dyspnea. The scan protocol included standard cardiac imaging and dual-sequence quantitative stress perfusion. Standard parameters were compared to 17 healthy controls from our institution. Quantitative perfusion was compared to published values of healthy controls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The stress myocardial blood flow (MBF) was significantly lower [31.8 &#xb1; 5.1 vs. 37.8 &#xb1; 6.0 (&#x3bc;l/g/beat), <i>P</i> &lt; 0.001] and the T2 relaxation time was significantly higher (46.2 &#xb1; 3.6 vs. 42.7 &#xb1; 2.8 ms, <i>P</i> = 0.002) post-COVID-19 compared to healthy controls. Stress MBF and T1 and T2 relaxation times were not correlated to the COVID-19 severity (Spearman <i>r</i> = -0.302, -0.070, and -0.297, respectively) or the presence of symptoms. The stress MBF showed a U-shaped relation to time from PCR to CMR, no correlation to T1 relaxation time, and a negative correlation to T2 relaxation time (Pearson <i>r</i> = -0.446, <i>P</i> = 0.029).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">While we found a significantly reduced microvascular perfusion post-COVID-19 compared to healthy controls, this reduction was not related to symptoms or COVID-19 severity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Doeblin, Steinbeis, Scannell, Goetze, Al-Tabatabaee, Erley, Faragli, Pr&#xf6;pper, Witzenrath, Zoller, Stehning, Gerhardt, S&#xe1;nchez-Gonz&#xe1;lez, Alskaf, K&#xfc;hne, Pieske, Tsch&#xf6;pe, Chiribiri and Kelle.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Doeblin</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, German Heart Center Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research (DZHK), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinbeis</LastName><ForeName>Fridolin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Respiratory Medicine, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scannell</LastName><ForeName>Cian M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goetze</LastName><ForeName>Collin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, German Heart Center Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Tabatabaee</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, German Heart Center Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erley</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, German Heart Center Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faragli</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, German Heart Center Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pr&#xf6;pper</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, German Heart Center Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witzenrath</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Respiratory Medicine, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoller</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Respiratory Medicine, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stehning</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Science, Philips Healthcare, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerhardt</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research (DZHK), Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrative Vascular Biology Laboratory, Max-Delbr&#xfc;ck Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Gonz&#xe1;lez</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Philips Healthcare, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alskaf</LastName><ForeName>Ebraham</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;hne</LastName><ForeName>Titus</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research (DZHK), Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Congenital Heart Disease, German Heart Center Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pieske</LastName><ForeName>Burkert</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, German Heart Center Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research (DZHK), Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Campus Virchow Klinikum, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsch&#xf6;pe</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research (DZHK), Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Campus Virchow Klinikum, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charite (BIH), Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiribiri</LastName><ForeName>Amedeo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelle</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, German Heart Center Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research (DZHK), Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Campus Virchow Klinikum, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cardiovasc Med</MedlineTA><NlmUniqueID>101653388</NlmUniqueID><ISSNLinking>2297-055X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CMR</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">long COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">microvascular disease</Keyword><Keyword MajorTopicYN="N">quantitative perfusion</Keyword></KeywordList><CoiStatement>PD owns stock of Siemens and Bayer. AF was a shareholder of BOCAhealthcare GmbH. CS was an employer of Philips Healthcare. BP reported receiving personal fees from Bayer, Bristol Myers Squib, Daiichi Sankyo, Medscape, MSD, Novartis, Stealth Peptides, and Vifor Pharma, and grants and personal fees from Astra-Zeneca. CS and JS-G were employees of Philips Healthcare. CT, BP, and SK received funding from the DZHK (German Centre for Cardiovascular Research) and by the BMBF (German Ministry of Education and Research) and personal fees from Servier, outside of the current work. SK received an unrestricted research grant from Philips Healthcare and received lecture honoraria from Medis, NL. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>17</Day><Hour>2</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35711381</ArticleId><ArticleId IdType="pmc">PMC9197432</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2022.877416</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. (2020) 324:603&#x2013;5. 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini D, Kawakami R, Guagliumi G, Sakamoto A, Kawai K, Gianatti A, et al. Microthrombi as a major cause of cardiac injury in COVID-19: a pathologic study. Circulation. (2021) 143:1031&#x2013;42. 10.1161/circulationaha.120.051828</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.120.051828</ArticleId><ArticleId IdType="pubmed">33480806</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Linthout S, Klingel K, Tschope C. SARS-CoV-2-related myocarditis-like syndromes Shakespeare&#x2019;s question: what&#x2019;s in a name? Eur J Heart Fail. (2020) 22:922&#x2013;5. 10.1002/ejhf.1899</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.1899</ArticleId><ArticleId IdType="pmc">PMC7276849</ArticleId><ArticleId IdType="pubmed">32430971</ArticleId></ArticleIdList></Reference><Reference><Citation>Doeblin P, Kelle S. Going after COVID-19-Myocarditis. Eur Heart J Cardiovasc Imaging. (2021) 22:852&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8194973</ArticleId><ArticleId IdType="pubmed">34080005</ArticleId></ArticleIdList></Reference><Reference><Citation>Drakos S, Chatzantonis G, Bietenbeck M, Evers G, Schulze AB, Mohr M, et al. A cardiovascular magnetic resonance imaging-based pilot study to assess coronary microvascular disease in COVID-19 patients. Sci Rep. (2021) 11:15667. 10.1038/s41598-021-95277-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95277-z</ArticleId><ArticleId IdType="pmc">PMC8329060</ArticleId><ArticleId IdType="pubmed">34341436</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization [WHO]. COVID-19 Clinical Management: Living Guidance. Geneva: WHO;  (2021). Available online at: https://apps.who.int/iris/handle/10665/338882</Citation></Reference><Reference><Citation>Vasu S, Bandettini WP, Hsu LY, Kellman P, Leung S, Mancini C, et al. Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson. (2013) 15:85. 10.1186/1532-429X-15-85</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1532-429X-15-85</ArticleId><ArticleId IdType="pmc">PMC3851492</ArticleId><ArticleId IdType="pubmed">24063278</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelle S, Bucciarelli-Ducci C, Judd RM, Kwong RY, Simonetti O, Plein S, et al. Society for Cardiovascular Magnetic Resonance (SCMR) recommended CMR protocols for scanning patients with active or convalescent phase COVID-19 infection. J Cardiovasc Magn Reson. (2020) 22:61. 10.1186/s12968-020-00656-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12968-020-00656-6</ArticleId><ArticleId IdType="pmc">PMC7467754</ArticleId><ArticleId IdType="pubmed">32878639</ArticleId></ArticleIdList></Reference><Reference><Citation>Scannell CM, Veta M, Villa ADM, Sammut EC, Lee J, Breeuwer M, et al. Deep-learning-based preprocessing for quantitative myocardial perfusion MRI. J Magn Reson Imaging. (2020) 51:1689&#x2013;96. 10.1002/jmri.26983</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmri.26983</ArticleId><ArticleId IdType="pmc">PMC7317373</ArticleId><ArticleId IdType="pubmed">31710769</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Gonzalez J, Fernandez-Jimenez R, Nothnagel ND, Lopez-Martin G, Fuster V, Ibanez B. Optimization of dual-saturation single bolus acquisition for quantitative cardiac perfusion and myocardial blood flow maps. J Cardiovasc Magn Reson. (2015) 17:21. 10.1186/s12968-015-0116-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12968-015-0116-2</ArticleId><ArticleId IdType="pmc">PMC4332925</ArticleId><ArticleId IdType="pubmed">25880970</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. (2018) 72:3158&#x2013;76. 10.1016/j.jacc.2018.09.072</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.09.072</ArticleId><ArticleId IdType="pubmed">30545455</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudt A, Jorres RA, Hinterberger T, Lehnen N, Loew T, Budweiser S. Associations of post-acute COVID syndrome with physiological and clinical measures 10 months after hospitalization in patients of the first wave. Eur J Intern Med. (2022) 95:50&#x2013;60. 10.1016/j.ejim.2021.10.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.10.031</ArticleId><ArticleId IdType="pmc">PMC8612867</ArticleId><ArticleId IdType="pubmed">34838369</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>